Scott Davis1, Dana K Mirick. 1. Program In Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center and Department of Epidemiology, University of Washington, Seattle, WA 98109-1024, USA. sdavis@fhcrc.org
Abstract
PURPOSE: To investigate whether the use of commonly-prescribed medications, primarily antihypertensives and antidepressants, is associated with an increased risk of breast cancer. METHODS: Participants from a population-based case-control study were re-contacted 5-8 years after the original study regarding prescription and non-prescription medication use during the 10 years prior to diagnosis. Controls (n = 647) were frequency-matched to the cases (n = 600) by 5-year age groups. Medication use information was obtained during a telephone interview, and participants were sent the questionnaire in advance to facilitate recall. Odds ratios and 95% confidence intervals were estimated using conditional logistic regression. RESULTS: A slightly increased risk of breast cancer was associated with use of calcium channel blockers (CCBs), but there was no trend with increasing duration or recency of use. Breast cancer risk was not associated with use of antidepressants, beta blockers, corticosteroids, or non-steroidal anti-inflammatory drugs. Results were similar when analyses were restricted to cases with localized disease. CONCLUSIONS: These results support previous findings that CCBs may be associated with modest increases in breast cancer risk, but not findings that non-steroidal anti-inflammatory use reduces risk.
PURPOSE: To investigate whether the use of commonly-prescribed medications, primarily antihypertensives and antidepressants, is associated with an increased risk of breast cancer. METHODS: Participants from a population-based case-control study were re-contacted 5-8 years after the original study regarding prescription and non-prescription medication use during the 10 years prior to diagnosis. Controls (n = 647) were frequency-matched to the cases (n = 600) by 5-year age groups. Medication use information was obtained during a telephone interview, and participants were sent the questionnaire in advance to facilitate recall. Odds ratios and 95% confidence intervals were estimated using conditional logistic regression. RESULTS: A slightly increased risk of breast cancer was associated with use of calcium channel blockers (CCBs), but there was no trend with increasing duration or recency of use. Breast cancer risk was not associated with use of antidepressants, beta blockers, corticosteroids, or non-steroidal anti-inflammatory drugs. Results were similar when analyses were restricted to cases with localized disease. CONCLUSIONS: These results support previous findings that CCBs may be associated with modest increases in breast cancer risk, but not findings that non-steroidal anti-inflammatory use reduces risk.
Authors: Eric J Jacobs; Michael J Thun; Cari J Connell; Carmen Rodriguez; S Jane Henley; Heather S Feigelson; Alpa V Patel; W Dana Flanders; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-01 Impact factor: 4.254
Authors: L Rosenberg; R S Rao; J R Palmer; B L Strom; P D Stolley; A G Zauber; M E Warshauer; S Shapiro Journal: JAMA Date: 1998-04-01 Impact factor: 56.272
Authors: D J Hole; C R Gillis; I R McCallum; G T McInnes; P L MacKinnon; P A Meredith; L S Murray; J W Robertson; A F Lever Journal: J Hypertens Date: 1998-01 Impact factor: 4.844
Authors: Christopher I Li; Kathleen E Malone; Noel S Weiss; Denise M Boudreau; Kara L Cushing-Haugen; Janet R Daling Journal: Cancer Date: 2003-10-01 Impact factor: 6.860
Authors: Mary Beth Terry; Marilie D Gammon; Fang Fang Zhang; Heba Tawfik; Susan L Teitelbaum; Julie A Britton; Kotha Subbaramaiah; Andrew J Dannenberg; Alfred I Neugut Journal: JAMA Date: 2004-05-26 Impact factor: 56.272
Authors: Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: Robert W Mathes; Kathleen E Malone; Janet R Daling; Scott Davis; Sylvia M Lucas; Peggy L Porter; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Deirdre P Cronin-Fenton; Lars Pedersen; Timothy L Lash; Søren Friis; John A Baron; Henrik T Sørensen Journal: Breast Cancer Res Date: 2010-03-01 Impact factor: 6.466
Authors: Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Jessica Chubak; Diana S M Buist; Denise M Boudreau; Mary Anne Rossing; Thomas Lumley; Noel S Weiss Journal: Breast Cancer Res Treat Date: 2007-12-06 Impact factor: 4.872
Authors: Yuxiu Xie; Men Wang; Peng Xu; Yujiao Deng; Yi Zheng; Si Yang; Ying Wu; Zhen Zhai; Dai Zhang; Na Li; Nan Wang; Jing Cheng; Zhijun Dai Journal: Front Pharmacol Date: 2021-05-13 Impact factor: 5.810
Authors: Albert Hofman; Cornelia M van Duijn; Oscar H Franco; M Arfan Ikram; Harry L A Janssen; Caroline C W Klaver; Ernst J Kuipers; Tamar E C Nijsten; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Jacqueline C M Witteman Journal: Eur J Epidemiol Date: 2011-08-30 Impact factor: 8.082
Authors: Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman Journal: Eur J Epidemiol Date: 2009 Impact factor: 8.082